SCHEMBL4228071

SCHEMBL4228071

Cc1cc(CC(C)(C)OC(N)=O)cc(C)c1Oc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
ALDH1A1 P00352 3/20 0.43
HTT P42858 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
LMNA P02545 2/20 0.43
MITF O75030 1/20 0.43
CCR6 P51684 1/20 0.43
KMT2A Q03164 5/20 0.40
MEN1 O00255 4/20 0.40
KDM4E B2RXH2 2/20 0.39
NPC1 O15118 1/20 0.38
MAPK1 P28482 1/20 0.38
RAB9A P51151 1/20 0.38
MYOC Q99972 1/20 0.38
POLB P06746 1/20 0.37
BCL9 O00512 1/20 0.37
CTNNB1 P35222 1/20 0.37
SRD5A2 P31213 1/20 0.37
MAOB P27338 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4240320 0.87 ALDH1A1 (0.42) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL4238193 0.86 MEN1 (0.46) MAPTALDH1A1HTTSMN1; SMN2NPSR1
SCHEMBL4228116 0.82 ALDH1A1 (0.44) MAPTALDH1A1KMT2AMEN1PKM
SCHEMBL4240945 0.80 ALDH1A1 (0.39) MAPTALDH1A1HTTSMN1; SMN2NPSR1
SCHEMBL4233545 0.80 TDP2 (0.47) MAPTALDH1A1HTTSMN1; SMN2LMNA
SCHEMBL4237809 0.79 PDE7A (0.54) MAPTALDH1A1SMN1; SMN2NPSR1LMNA
SCHEMBL4238971 0.79 TTR (0.48) MAPTALDH1A1SMN1; SMN2LMNAKMT2A
SCHEMBL4227934 0.79 HSPB1 (0.53) MAPTALDH1A1KMT2AMEN1PKM
SCHEMBL4237489 0.79 TBXA2R (0.41) MAPTALDH1A1HTTLMNAKMT2A
SCHEMBL4236941 0.78 HSPB1 (0.40) MAPTALDH1A1KMT2AMEN1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R MAPT 1398/4885ALDH1A1 4542/4885HTT 618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.